--- title: "WEIGAO GROUP: Weigao Orthopaedic expects the net profit attributable to the parent company in 2024 to be between 200 million and 240 million yuan, an increase of 78.07%-113.68% year-on-year" type: "News" locale: "en" url: "https://longbridge.com/en/news/225673120.md" description: "WEIGAO GROUP expects its subsidiary WeigaoOrthopaedic to achieve a net profit attributable to the parent company of 200 million to 240 million yuan in 2024, a year-on-year increase of 78.07% to 113.68%. The company will actively implement the volume-based procurement policy, adjust its business strategy, optimize its product line and cost control, strengthen cooperation with medical institutions, and explore diversified market channels to increase market share and customer coverage. At the same time, WeigaoOrthopaedic will promote the development of new production lines and new markets to enhance its international brand influence" datetime: "2025-01-21T10:57:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/225673120.md) - [en](https://longbridge.com/en/news/225673120.md) - [zh-HK](https://longbridge.com/zh-HK/news/225673120.md) --- # WEIGAO GROUP: Weigao Orthopaedic expects the net profit attributable to the parent company in 2024 to be between 200 million and 240 million yuan, an increase of 78.07%-113.68% year-on-year According to the Zhitong Finance APP, WEIGAO GROUP (01066) announced that WeigaoOrthopaedic (688161.SH) is expected to achieve a net profit attributable to shareholders of the listed company of 200 million to 240 million yuan in 2024, an increase of 78.07% to 113.68% year-on-year; it is expected that the net profit after deducting non-recurring gains and losses will be approximately 191 million to 231 million yuan, an increase of 77.02% to 114.09% year-on-year. In 2024, the volume-based procurement of orthopedic consumables will fully implement and enter a stable period. WeigaoOrthopaedic actively implements the volume-based procurement policy, proactively adjusts its business strategy, re-plans its product line, optimizes cost control, strengthens cooperation with medical institutions, and explores diversified market channels to maximize market share and customer coverage, achieving performance growth. WeigaoOrthopaedic continues to promote the transformation of its sales model, creating collaborative sales capabilities focused on key surgical procedures, and continuously enhancing clinical service capabilities; implementing a major customer strategy to increase end customer stickiness and improve customer coverage; at the same time, continuously optimizing product structure, leading changes in clinical procedures, promoting collaborative sales of products, and improving product gross margins and market share. The new production lines and new markets of WeigaoOrthopaedic are developing rapidly, with new business lines such as artificial bones, sports medicine, and minimally invasive spine surgery steadily advancing, laying a solid foundation for new business layout; overseas product registration has been fully launched and implemented, gradually increasing international brand influence through market academic promotion. WeigaoOrthopaedic strengthens refined performance management, reasonably plans the investment of market expenses, effectively reduces the sales expense ratio through optimizing marketing structure and personnel structure, channel integration, and refined management of market expenses. It reorganizes channel inventory and systematically manages the inventory of self-built warehouses, consignment warehouses, and third-party logistics platforms, improving supply chain response speed and significantly enhancing product turnover efficiency. In 2025, WeigaoOrthopaedic will continue to promote the development layout in the field of orthopedic innovation, increase R&D investment in key products, and continuously expand and solidify the orthopedic innovation product matrix through independent research and development and external mergers and acquisitions; continuously improve the professional level of the sales organization and further enhance collaborative sales capabilities; accelerate the expansion of overseas business, targeting blank markets and strategic markets overseas, with multiple strategies advancing simultaneously to enhance international brand influence and increase market share ### Related Stocks - [01066.HK](https://longbridge.com/en/quote/01066.HK.md) - [688161.CN](https://longbridge.com/en/quote/688161.CN.md) - [301290.CN](https://longbridge.com/en/quote/301290.CN.md) - [688581.CN](https://longbridge.com/en/quote/688581.CN.md) - [002277.CN](https://longbridge.com/en/quote/002277.CN.md) - [00853.HK](https://longbridge.com/en/quote/00853.HK.md) - [688576.CN](https://longbridge.com/en/quote/688576.CN.md) ## Related News & Research - [Key facts: Li Auto L9 uses FlexNoC/Magillem for 2,560 TOPS; shares fall](https://longbridge.com/en/news/286979573.md) - [Pure Tungsten Completes Merger with GB Innovation Co., Ltd., Advancing Toward Near-Term Production and Planned Public Listing](https://longbridge.com/en/news/286944364.md) - [China's top flash-memory chipmaker YMTC begins pre-IPO coaching talks with investment bank](https://longbridge.com/en/news/286879811.md) - [Kioxia weighs plan to float ADSs against conditions](https://longbridge.com/en/news/286796988.md) - [Tesla’s $250 Million Germany Bet Is Interesting. It’s Spending More Before It Has the Payoff.](https://longbridge.com/en/news/286673310.md)